TREATMENT OF ACUTE WHEEZING AND DYSPNEA ATTACKS IN CHILDREN UNDER 2 YEARS OLD - INHALATION OF FENOTEROL PLUS IPRATROPIUM BROMIDE VERSUS FENOTEROL

被引:6
|
作者
NASPITZ, CK [1 ]
SOLE, D [1 ]
机构
[1] ESCOLA PAULISTA MED SCH,DEPT PEDIAT,IMMUNOL & RHEUMATOL CLIN,BR-04023 SAO PAULO,BRAZIL
关键词
D O I
10.3109/02770909209048939
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Two treatment regimens for the initial treatment of acute wheezing were evaluated in 61 wheezing infants. Thirty-one patients received fenoterol (F) (0.1 mg/kg) and placebo (P) and 30 patients received fenoterol (F) (0.1 mg/kg) plus a fixed dose of ipratropium bromide (IB) (50-mu-g). Both groups received the drugs by inhalation using an ultrasonic nebulizer and face mask. A clinical score system based on wheezing and rib cage retraction was established and evaluations were performed before and at 15, 30, and 45 minutes after treatment. After the last evaluation based on the clinical score, it was decided whether to repeat or not to repeat the treatment. Our results showed that a combination of a beta agonist and ipratropium bromide (FB) was more effective than a beta agonist alone (F) in reducing wheezing and dyspnea during an acute attack (63.4 versus 25.8%; p<0.05).
引用
收藏
页码:253 / 258
页数:6
相关论文
共 45 条
  • [11] BRONCHODILATOR EFFECT OF THE ASSOCIATION IPRATROPIUM BROMIDE PLUS FENOTEROL (LOW-DOSES) VERSUS TERBUTALINE AND SALBUTAMOL IN BRONCHITIC PATIENTS
    MARIN, J
    SERVERA, E
    VERGARA, P
    DIAZ, J
    CALPE, JL
    PEREZ, D
    BARBAL, JG
    RESPIRATION, 1986, 50 : 276 - 279
  • [12] THE COMBINATION OF FENOTEROL AND IPRATROPIUM BROMIDE IN BRONCHIAL-ASTHMA - COMPARISON OF THE ACUTE EFFECTS OF 2 DIFFERENT DOSAGES
    BONSIGNORE, G
    BELLIA, V
    PERALTA, G
    ALESSI, N
    MIGLIARA, G
    RESPIRATION, 1986, 50 : 148 - 151
  • [13] EFFECTS OF NEBULIZED FENOTEROL, ASSOCIATED WITH IPRATROPIUM OR STEROIDS, ON THE HEART-RATE OF INFANTS UNDER ONE YEAR OF AGE WITH ACUTE WHEEZING
    MALLOL, J
    MUNOZ, R
    PUPPO, H
    ULLOA, V
    TORO, O
    GIRARDI, G
    BARRUETO, L
    PEDIATRIC PULMONOLOGY, 1987, 3 (02) : 83 - 85
  • [14] TREATMENT OF ACUTE ATTACKS OF BRONCHIAL-ASTHMA - A COMPARATIVE-STUDY OF EPINEPHRINE (SUBCUTANEOUS) AND FENOTEROL (INHALATION)
    NASPITZ, CK
    SOLE, D
    WANDALSEN, N
    ANNALS OF ALLERGY, 1987, 59 (01): : 21 - 24
  • [15] PROTECTIVE EFFECT OF FENOTEROL SPRAY, IPRATROPIUM BROMIDE PLUS FENOTEROL SPRAY, AND ORAL CLENBUTEROL, ON EXERCISE-INDUCED ASTHMA IN CHILDREN - DOUBLE-BLIND CONTROLLED AND RANDOMIZED CLINICAL-TRIAL
    AGOSTINI, M
    BARLOCCO, G
    MASTELLA, G
    EUROPEAN JOURNAL OF RESPIRATORY DISEASES, 1983, 64 : 529 - 532
  • [16] ON THE EFFECTS OF NEBULIZED FENOTEROL, ASSOCIATED WITH IPRATROPIUM OR STEROLIS, ON THE HEART-RATE OF INFANTS UNDER ONE YEAR OF AGE WITH ACUTE WHEEZING - REPLY
    MALLOL, J
    PEDIATRIC PULMONOLOGY, 1988, 4 (01) : 62 - 62
  • [17] Ipratropium bromide plus nebulized albuterol for the treatment of hospitalized children with acute asthma
    Craven, D
    Kercsmar, CM
    Myers, TR
    O'Riordan, MA
    Golonka, G
    Moore, S
    JOURNAL OF PEDIATRICS, 2001, 138 (01): : 51 - 58
  • [18] Efficacy and safety of Ipratropium bromide plus fenoterol inhaled via Respimat® Soft Mist™ inhaler vs. a conventional metered dose inhaler plus Spacer in children with asthma
    von Berg, A
    Jeena, PM
    Soemantri, PA
    Vertruyen, A
    Schmidt, P
    Gerken, F
    Razzouk, H
    PEDIATRIC PULMONOLOGY, 2004, 37 (03) : 264 - 272
  • [19] THE IMPACT OF REGIONAL DATA ON COST-EFFECTIVENESS RESULTS OF SALMETEROL/FLUTICASONE PROPIONATE (SAL/FP) plus FENOTEROL/IPRATROPIUM BROMIDE (FEN/IB) VERSUS FEN/IB ONLY IN COPD TREATMENT
    Yagudina, R.
    Kulikov, A.
    Chuchalin, A. G.
    Belevsky, A.
    Demko, I., V
    Lomakin, A.
    Shchurov, D.
    VALUE IN HEALTH, 2011, 14 (07) : A494 - A494
  • [20] Long-term efficacy and safety of ipratropium bromide plus fenoterol via Respimat® Soft Mist™ inhaler (SMI) versus a pressurised metered-dose inhaler in asthma
    Vincken, W
    Bantje, T
    Middle, MV
    Gerken, F
    Moonen, D
    CLINICAL DRUG INVESTIGATION, 2004, 24 (01) : 17 - 28